5-year-old girl injured in crash involving Britt Reid functioning like a baby, attorney says
Ariel Young diagnosed with traumatic brain injury
Provided
A photo of the 5-year-old girl that was critically injured in a crash along Interstate 435 in Kansas City, Missouri, on Feb. 5, 2021.
By: KSHB Staff
and last updated 2021-04-15 16:13:41-04
KANSAS CITY, Mo. â The
5-year-old girl who was critically injured in a
crash that involved former Chiefs assistant coach Britt Reid will âendure a traumatic brain injury for the rest of her life,â according to a lawyer representing her family. The girl, Ariel Young, is now back home recovering.
What Parents Need to Know About Multisystem Inflammatory Syndrome, an Illness Related to COVID-19
msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
Improving Quality of THC-Based Medications Proving to be Lucrative Path for Cannabis Companies
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
MS Hospital Visits Increase in Warmer Weather
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
F. Hoffmann-La Roche Ltd: Roche s Evrysdi continues to improve motor function and survival in babies with Type 1 Spinal Muscular Atrophy (SMA)
Evrysdi increased survival and reduced need for permanent ventilation
Evrysdi has proven efficacy across adults, children and babies 2 months and older
Basel, 15 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new 2-year data from Part 2 of FIREFISH, a Phase 2/3 global study evaluating Evrysdi (risdiplam) in infants aged 1-7 months at enrollment with symptomatic Type 1 spinal muscular atrophy (SMA). The data showed Evrysdi continued to improve motor function between months 12 and 24, including the ability to sit without support. The study also showed Evrysdi continued to improve survival, improve ability to feed orally and reduce the need for permanent ventilation . Exploratory data suggested Evrysdi continued to improve the ability to swallow and reduce hospitalisations compared to the natural course of Type 1 SMA. Safety f